Sarepta Therapeutics, Inc.
SRPT · Nasdaq · USD · Market cap $1.6B · 835 employees
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for…
PASS · Titan Ethical · score 70.0Price as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price13.33 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readDistribution, as of 16 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans to puts (put/call 6.62)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $24.48 to $26.66, base estimate $25.00 (screen dated 2026-11-20).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 6.62, read 2026-11-20
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Sarepta Therapeutics, Inc. holds its Distribution at $13.33. Consolidating, no directional conviction, held for 136 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 136 days |
| Price at the screen | $13.33 |
| Valuation | 738.50 trailing · 9.96 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.45 |
Five Screens: SRPT's Results
PASS. All five recorded results clear their limits.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 31.04% | Below 33% | Pass |
| Interest-bearing cash | 4.13% | Below 33% | Pass |
| Receivables | 35.81% | Below 49% | Pass |
| Revenue purity | 1.67% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Clears, in Plain English
Sarepta Therapeutics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when SRPT's ethical verdict changes
Today SRPT passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 47% discount to our $25.00 fair value.
USD, 2026-11-20 screen. A 46.7% under base.
Street: 22 covering, consensus Hold. Average target +50%.
Rare disease hopes meet shrinking revenue
Imagine families waiting on a single genetic therapy to change a child's life. Sarepta develops exactly those RNA and gene treatments for rare conditions, yet the business shows no lift. We pass because revenue is falling and the numbers offer nothing to build a case around.
Forward earnings sit at seven times but top line slipped two percent, profit margins reach only three percent and return on equity is five percent. Analysts call it a hold with a twenty dollar median target, well below our fair value mark. The ethical screen clears yet opportunity stays at none.
An unknown moat in a trial heavy field leaves the firm exposed to sudden setbacks that can wipe out years of work. Low returns and flat growth point to a business that has yet to prove durable scale. Analysis, not advice.
| Forward P/E | 10.0xvery cheap relative to earnings |
| Trailing P/E | 738.5xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.02 |
| EPS, forward | 1.48 |
| Revenue growth | -4.5%revenue is shrinking |
| Profit margin | -5.9%currently unprofitable |
| Return on equity | -8.0%not currently earning a positive return on equity |
| FCF yield | 6.90% |
| Debt to equity | 0.71moderate, manageable leverage |
| Current ratio | 3.46comfortably covers its short-term bills |
| Beta | 0.45barely tracks the market's swings |
| Short interest, float | 0.22% |
| 52-week range | 14.59 - 24.68 |
| Market cap | $1.6B |
| Employees | 835 |
SRPT-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Since the last review it saw its composite score rise.
Earnings landed in this window. Ethical screening: PASS.
Written on its date, before the outcome; never pruned.
- DraftKings downgraded, Sarepta upgraded: Wall Street's top analyst calls Yahoo Finance · 11d ago
- Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance Yahoo Finance · 12d ago
- Learn Why The Bull Case For Sarepta Therapeutics Stock Could Change Following Raised Revenue Guidance Yahoo Finance · 14d ago
- Sarepta (SRPT) Q3 2026 Earnings Call Transcript Yahoo Finance · 15d ago
- SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline Yahoo Finance · 15d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $19.40 | -22.1% | · | $779 | -22.1% |
| 2 months | $21.18 | -28.7% | · | $713 | -28.7% |
| 3 months | $17.04 | -11.3% | · | $887 | -11.3% |
| 6 months | $21.75 | -30.5% | · | $695 | -30.5% |
| 1 year | $39.07 | -61.3% | · | $387 | -61.3% |
| 2 years | $122.59 | -87.7% | · | $123 | -87.7% |
| 3 years | $127.67 | -88.2% | · | $118 | -88.2% |
| 5 years | $86.00 | -82.4% | · | $176 | -82.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SRPT does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.